| Name | Title | Contact Details |
|---|---|---|
Helen Bellwood |
Chief Financial Officer | Profile |
Michael O`Connor |
Chief Financial Officer | Profile |
The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
great healthworks is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Skingenix is a Arcadia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.